Curis (CRIS) Trading 8.7% Higher
Curis, Inc. (NASDAQ:CRIS) traded up 8.7% on Tuesday . The stock traded as high as $0.76 and last traded at $0.75. 2,556,147 shares traded hands during mid-day trading, an increase of 51% from the average session volume of 1,688,473 shares. The stock had previously closed at $0.69.
Several equities research analysts have weighed in on the stock. Zacks Investment Research lowered shares of Curis from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Guggenheim assumed coverage on shares of Curis in a report on Monday, October 23rd. They set a “buy” rating and a $7.00 price objective on the stock. Three research analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $6.50.
The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $122.89, a price-to-earnings ratio of -1.78 and a beta of 1.63.
In related news, CEO Ali Ph.D. Fattaey acquired 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The shares were acquired at an average cost of $1.06 per share, for a total transaction of $53,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 115,890 shares in the company, valued at approximately $122,843.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.07% of the company’s stock.
Several large investors have recently modified their holdings of CRIS. FNY Partners Fund LP raised its holdings in shares of Curis by 350.0% during the third quarter. FNY Partners Fund LP now owns 67,500 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 52,500 shares during the period. OxFORD Asset Management LLP acquired a new stake in shares of Curis during the second quarter worth $115,000. Voya Investment Management LLC grew its position in Curis by 21.8% in the second quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 12,207 shares in the last quarter. Alliancebernstein L.P. grew its position in Curis by 338.7% in the second quarter. Alliancebernstein L.P. now owns 83,800 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 64,700 shares in the last quarter. Finally, SG Americas Securities LLC grew its position in Curis by 514.0% in the fourth quarter. SG Americas Securities LLC now owns 269,128 shares of the biotechnology company’s stock valued at $188,000 after purchasing an additional 225,295 shares in the last quarter. Institutional investors and hedge funds own 55.22% of the company’s stock.
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.